Paris (ots/PRNewswire) – Two studies presented at World Diabetes Congress 2011 provide further evidence of the benefits to patients of early glycemic control on co-morbidities Sanofi announced today new results from sub-analyses of the First Basal INsulin Evaluation in Asia (FINE Asia) Registry study,[1] and the Cardiovascular Risk Evaluation in People with Type 2 Diabetes [...]
Tag Archive > Cardiovascular Risk
Panasonic’s CardioHealth Station Improves Patient Outcomes Through Early Diagnosis in Primary Care
Dusseldorf, Germany, November 17 (ots/PRNewswire) – Panasonic announced today the European availability of its innovative ultrasound tool for personalized preventive medicine, the CardioHealth Station, at renowned medical trade fair MEDICA in Dusseldorf, Germany (booth 9E47). The device, which is FDA cleared and recently secured its CE registration mark, is designed to assist medical professionals in [...]
XLVIII ERA-EDTA Congress in Prague from 23 June to 26 June 2011
Prag (ots) – The congress of the ERA-EDTA (European Renal Association and European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. You are cordially invited to attend this Congress. The Opening Press Conference will be held on Thursday 23rd June, 11 am (Corinthia Hotel). Topic: Can the [...]
Chronic Kidney Disease and Cardiovascular Risk
Strasbourg, France (ots/PRNewswire) – The European Kidney Health Alliance (EKHA) and World Kidney Day (WKD) organisations today call for urgent European Union (EU) action to curb the increasing burden of chronic kidney disease (CKD) and associated diseases. The Members of European Parliament (MEP) Group for Kidney Health met with some of Europe’s top kidney experts [...]
Study Shows Cardiovascular Deaths in Europe Could Be Prevented
Prague, November 8 (ots/PRNewswire) – Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year.[i] Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.[ii] The European Study on Cardiovascular Risk Prevention [...]
New JUPITER Analysis Demonstrates CRESTORTM (rosuvastatin) Significantly Reduces Major Cardiovascular Events in High Risk Patients
London (ots/PRNewswire) – A post-hoc-analysis from JUPITER published in the European Heart Journal shows CRESTOR(TM) (rosuvastatin) 20 mg significantly reduced major cardiovascular (CV) events, defined as the combined end-point of CV death, stroke and myocardial infarction, compared to placebo, by 50% (p=0.028; CI 0.27-0.93) in high risk patients with a 10-year Framingham risk score >20% [...]
Patients with Hypertension at Risk Due to Physician Inertia
Oslo, June 21, 2010 (ots/PRNewswire) – Data announced for the first time at ESH suggest that patients with hypertension are at increased cardiovascular risk due to clinician inertia, because physicians are failing to treat targets set by accepted ESH-ESC (European Society of Hypertension and European Society of Cardiology) guidelines for the management of arterial hypertension [...]
ACCORD-Lipidstudie bringt Patienten mit Typ-2-Diabetes und atherogener Dyslipidämie neue Hoffnung, berichtet eine internationale wissenschaftliche Stiftung
Atlanta, Georgia, March 17, 2010 (ots/PRNewswire) – Das kardiovaskuläre Risiko kann bei Typ-2-Diabetikern um zusätzliche 31 Prozent reduziert werden, die eine atherogene Dyslipidämie mit erhöhten Triglyceriden (TG: 204 mg/dl oder 2,3 mmol/l oder höher) und erniedrigten HDL-Cholesterin-Werten (HDL-C: 34 mg/dl oder 0,88 mmol/l oder weniger),. Dies wird dadurch erreicht, bei Kombination von Simvastatin mit Fenofibrat. [...]
Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation
Paris, November 16 (ots/PRNewswire) – – The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real Life global Survey Evaluating patients with Atrial Fibrillation), an international, cross-sectional, observational [...]
CRESTOR(R) Reduced the Risk of Cardiovascular Events in Elderly Patients in New Analysis of JUPITER
Barcelona (ots/PRNewswire) – A new analysis from the JUPITER study showed that CRESTOR(R) (rosuvastatin) 20mg reduced the composite primary end point of major cardiovascular (CV) events (combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p
